Radiopharm Theranostics Ltd
RAD
Company Profile
Business description
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.
Contact
62 Lygon Street
Suite 1, Level 3, Carlton South
MelbourneVIC3053
AUST: +61 398245254
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
14
Stocks News & Analysis
stocks
Weekly earnings wrap: Last week’s winners & losers
A mixed first week for company’s reporting on the ASX. Here’s everything you need to know
stocks
Alphabet earnings: Continued momentum on cloud and search as capital expenses set to mount
Strong fourth quarter earnings.
stocks
Eli Lilly earnings: Revenue increases reflect global demand for oral obesity therapies
We’ve raised our fair value estimate of Lilly stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,969.00 | 89.80 | -0.99% |
| CAC 40 | 8,238.17 | 23.99 | -0.29% |
| DAX 40 | 24,491.06 | 111.98 | -0.46% |
| Dow JONES (US) | 49,053.22 | 448.08 | -0.91% |
| FTSE 100 | 10,309.22 | 93.12 | -0.90% |
| HKSE | 26,885.24 | 37.92 | 0.14% |
| NASDAQ | 22,667.53 | 237.05 | -1.03% |
| Nikkei 225 | 53,317.62 | 500.42 | -0.93% |
| NZX 50 Index | 13,444.02 | 23.27 | -0.17% |
| S&P 500 | 6,821.72 | 61.00 | -0.89% |
| S&P/ASX 200 | 8,726.60 | 78.90 | -0.90% |
| SSE Composite Index | 4,075.03 | 0.88 | -0.02% |